| Summary: | Introduction and Objectives: Acute on chronic liver failure (ACLF) describe a state of severe liver dysfunction. Extracorporeal liver support (ECLS) is a system that performs filtration and detoxification functions within an external device with the goal of reducing mortality or bypassing liver transplantation. The objective was to evaluate the effects of the molecular absorbent recirculating system (MARS) and single-pass albumin dialysis (SPAD) in patients with acute-on-chronic in a tertiary Mexican hospital. Materials and Patients: : Retrospectively, a search was performed in the internal electronic system with patients who required MARS or SPAD from 2016 to 2022. Results: The results show a total of 18 patients with the diagnosis of acute on chronic liver failure who received treatment with MARS or SPAD. It was observed that 50% of the patients were women, with a mean age of 37.8 years.The cause of the chronic liver disease was autoimmune hepatitis in 5 cases, 5 primary biliary cholangitis, 3 as cryptogenic cirrhosis, 2 viral, 1 hepatocarcinoma, 1 metabolism errors and 1 graft rejection. Within the support therapies used, it was found that 28% of the patients received MARS and 72% received SPAD, with a total of 49 sessions.Clinically 77% of patients experienced improvement in hepatic encephalopathy and 66% improvement in renal function. At the end of the 90-day follow-up period, an overall survival rate of 52.94% was recorded. Conclusions: These findings support the effectiveness of MARS and SPAD as viable ECLS options in patients with ACLF. The positive results in the improvement of encephalopathy and renal function, together with the survival rate, indicate the potential of these therapeutic approaches in the management of patients in this clinical setting. The sample size was small, which may affect the generalizability of the results.
|
|---|